Ke-Rang Zhang (Kerang Zhang)

ORCID

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 5

Top Venues

Translational psychiatry

This page only lists publications with an associated author ORCID identifier.

Publications

Weifeng Mi, Xiaolan Di, Yiming Wang, Huafang Li, Xiufeng Xu, Lehua Li, Huaning Wang, Guoqiang Wang, Ke-Rang Zhang, Feng Tian, Jiong Luo, Chanjuan Yang, Yunfei Zhou, Shiping Xie, Hua Zhong, Bin Wu, Dong Yang, Zhenhua Chen, Yi Li, Jindong Chen, Shuyun Lv, Qizhong Yi, Zhiwei Jiang, Jingwei Tian, Hongyan Zhang
A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder. Translational psychiatry 13 (1) (2023)
Weifeng Mi, Xiaolan Di, Yiming Wang, Huafang Li, Xiufeng Xu, Lehua Li, Huaning Wang, Guoqiang Wang, Ke-Rang Zhang, Feng Tian, Jiong Luo, Chanjuan Yang, Yunfei Zhou, Shiping Xie, Hua Zhong, Bin Wu, Dong Yang, Zhenhua Chen, Yi Li, Jindong Chen, Shuyun Lv, Qizhong Yi, Zhiwei Jiang, Jingwei Tian, Hongyan Zhang
A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder. Translational psychiatry 13 (1) (2023)
Weifeng Mi, Xiaolan Di, Yiming Wang, Huafang Li, Xiufeng Xu, Lehua Li, Huaning Wang, Guoqiang Wang, Ke-Rang Zhang, Feng Tian, Jiong Luo, Chanjuan Yang, Yunfei Zhou, Shiping Xie, Hua Zhong, Bin Wu, Dong Yang, Zhenhua Chen, Yi Li, Jindong Chen, Shuyun Lv, Qizhong Yi, Zhiwei Jiang, Jingwei Tian, Hongyan Zhang
A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder. Translational psychiatry 13 (1) (2023)
Weifeng Mi, Xiaolan Di, Yiming Wang, Huafang Li, Xiufeng Xu, Lehua Li, Huaning Wang, Guoqiang Wang, Ke-Rang Zhang, Feng Tian, Jiong Luo, Chanjuan Yang, Yunfei Zhou, Shiping Xie, Hua Zhong, Bin Wu, Dong Yang, Zhenhua Chen, Yi Li, Jindong Chen, Shuyun Lv, Qizhong Yi, Zhiwei Jiang, Jingwei Tian, Hongyan Zhang
A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder. Translational psychiatry 13 (1) (2023)
Yu-Dan Ding, Xiao Chen, Zuo-Bing Chen, Le Li, Xue-Ying Li, Francisco Xavier Castellanos, Tong-Jian Bai, Qi-Jing Bo, Jun Cao, Zhi-Kai Chang, Guan-Mao Chen, Ning-Xuan Chen, Wei Chen, Chang Cheng, Yu-Qi Cheng, Xi-Long Cui, Jia Duan, Yi-Ru Fang, Qi-Yong Gong, Zheng-Hua Hou, Lan Hu, Li Kuang, Feng Li, Hui-Xian Li, Kai-Ming Li, Tao Li, Yan-Song Liu, Zhe-Ning Liu, Yi-Cheng Long, Bin Lu, Qing-Hua Luo, Hua-Qing Meng, Dai-Hui Peng, Hai-Tang Qiu, Jiang Qiu, Yue-Di Shen, Yu-Shu Shi, Tian-Mei Si, Yan-Qing Tang, Chuan-Yue Wang, Fei Wang, Kai Wang, Li Wang, Xiang Wang, Ying Wang, Yu-Wei Wang, Xiao-Ping Wu, Xin-Ran Wu, Chun-Ming Xie, Guang-Rong Xie, Hai-Yan Xie, Peng Xie, Xiu-Feng Xu, Hong Yang, Jian Yang, Jia-Shu Yao, Shu-Qiao Yao, Ying-Ying Yin, Yong-Gui Yuan, Yu-Feng Zang, Ai-Xia Zhang, Hong Zhang, Ke-Rang Zhang, Lei Zhang, Zhi-Jun Zhang, Jing-Ping Zhao, Ru-Bai Zhou, Yi-Ting Zhou, Jun-Juan Zhu, Zhi-Chen Zhu, Chao-Jie Zou, Xi-Nian Zuo, Chao-Gan Yan, Wen-Bin Guo
Reduced nucleus accumbens functional connectivity in reward network and default mode network in patients with recurrent major depressive disorder. Translational psychiatry 12 (1) (2022)

Ke-Rang Zhang.css-eqlu8i{font-size:small;padding-left:4px;} (Kerang Zhang)

Publication Activity (10 Years)

Top Topics

Top Venues

Ke-Rang Zhang (Kerang Zhang)